Cancer Therapy

Antisense Compound Acts Synergistically With Chemotherapy

Published in Cancer Weekly, July 31st, 2001

Genta Inc. (GNTA) announced the presentation of two scientific studies that documented the synergy between Genta's antisense compound, Genasense^TM, with drugs that are being used in ongoing, late-stage, clinical trials in patients with multiple myeloma and acute myeloid leukemia.

The experimental studies were presented on June 23-24, 2001, at the annual meeting of the European Hematology Association in Frankfurt, Germany. In the first presentation, investigators from the University of Texas-San Antonio showed that Bcl-2 (the target of Genasense) was a major factor in the resistance of myeloma to standard chemotherapy. Genasense treatment markedly reduced...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-07-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry